Project Grant P01HL180323
Award Date 8/15/25
Completion Date 7/31/30
Dollars Obligated $2.4M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $410,449 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to The Leland Stanford Junior University (Stanford University) on August 1, 2025. The funding supports research to develop novel synthetic biology strategies that would enable the quantitative and dynamic regulation of growth factors and cytokines produced from human induced pluripotent stem cell-derived endothelial cells (iPSC-ECs). The goal...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) is providing $331,344.00 to The Leland Stanford Junior University to investigate the gene regulatory mechanisms of the coronary artery disease gene PRDM16 and its impact on smooth muscle cell phenotypic modulation. The research aims to determine how PRDM16, an epigenetic modifier, regulates the transition of smooth muscle cells into protective "fibromyocytes"...
- This Project Grant award of $705,405 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to The Leland Stanford Junior University supports research focused on characterizing the role of adventitial fibroblasts in atherosclerosis. The research aims to identify new therapeutic targets and pathways related to this understudied cell population's influence on atherosclerotic plaque formation and calcification. The project will leverage single-cell genomics,...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $245,626 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Johns Hopkins University. The grant, with a project period from February 1, 2025 to January 31, 2027, will fund research to validate lipidomic signatures associated with right ventricular and pulmonary vascular dysfunction in pulmonary arterial hypertension (PAH). The project aims to replicate the researchers' preliminary findings on...
- The National Heart Lung and Blood Institute (NHLBI), through the Cardiovascular Diseases Research grant program (CFDA 93.837), awarded a $128,085 project grant to The Leland Stanford Junior University (Stanford University) to investigate the role of the COUP-TFII transcription factor in human vein development. The research aims to establish whether COUP-TFII is required for human vein endothelial cell specification and identify the specific protein domains of COUP-TFII involved. The project...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a 5-year, $165,888 Project Grant to The Leland Stanford Junior University (Stanford University) to conduct research on the role of the ZEB1 transcription factor in the development of coronary artery disease (CAD). The primary objective is to characterize and establish the causal role of ZEB1 in atherosclerosis development. The research will use a ZEB1 knockout mouse model to determine the transcriptional, epigenetic, and plaque...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $540,856 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Regents of the University of California, San Francisco (UCSF) on Dec 15, 2024. The goal of this 4-year project is to identify transcriptional regulators that control endocardial-specific gene expression and valve development, as well as understand the regulation and function of the SLC16A2 gene during heart injury and regeneration. The...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $775,720 project grant to Yale University under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) to conduct research on the role of endothelial protocadherins in vascular development and disease. The project aims to: 1) determine the effects of knocking out or inhibiting the protocadherin gamma (PCDHG) cluster in endothelial cells in mouse models of vascular inflammation, 2) elucidate the mechanism by which...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $162,486 to The Leland Stanford Junior University to engineer hematopoietic stem cells to produce B cells that secrete antibodies against PCSK9, a promising treatment for hypercholesterolemia. The research aims to develop a durable, lifelong therapeutic solution by using CRISPR/Cas9 genome editing to target an engineered antibody transgene into a safe-harbor site in...
- The National Heart Lung and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $147,486 project grant to Baylor College of Medicine to study the genetics of cardiovascular disease (CVD) across diverse and mixed-ancestry populations. The goal is to improve genetic testing for CVD and lipoprotein A, a lipoprotein that increases CVD risk, by evaluating the role of linkage disequilibrium and genetic structure. This ancestry-informed approach aims...